Results 181 to 190 of about 6,391 (198)
Some of the next articles are maybe not open access.
Preleukemia in Acute Lymphoblastic Leukemia
Acta Haematologica, 1981A patient who presented with preleukemia evolving into acute lymphoblastic leukemia is described. The preleukemic phase was characterized by a positive acidified serum lysis test (Ham test).
I. Ariel +2 more
openaire +3 more sources
Mitoxantrone in acute lymphoblastic leukemia
Cancer Treatment Reviews, 1983Mitoxantrone, 1,4-dihydroxy-5,8-bis[[2-[(2-hydroxyethyl)amino]ethylamino]]9,10 anthracenedione dihydrochloride, CL 232,215 (NSC 301739) is a synthetic aminoanthraquinone which binds to DNA (2, 17), and was designed to reduce or eliminate the cardiotoxicity seen with the structurally related anthracycline antibiotics (1).
Takao Ohnuma +4 more
openaire +3 more sources
Neonatal Acute Lymphoblastic Leukemia
Pediatric Emergency Care, 2020Abstract Acute lymphoblastic leukemia (ALL) in a neonate can have a similar clinical appearance to other serious pathology and should be considered in the ill-appearing infant. We present the case of a 24-hour-old male infant born to a mother with limited prenatal care who was brought to the pediatric emergency department with a rash and ...
Andrew L. Juergens +4 more
openaire +3 more sources
2007
Acute lymphoblastic leukemias (ALLs) are a group of hematological neoplasias defined by cytomorphology, cytochemistry, immunological markers, and more recently, molecular markers. The prognosis of ALL has much improved in the last 30 yr, especially in the age group between 2 and 10 yr, where most patients can be cured by chemotherapy.
Vishwas S. Sakhalkar, Reinhold Munker
openaire +2 more sources
Acute lymphoblastic leukemias (ALLs) are a group of hematological neoplasias defined by cytomorphology, cytochemistry, immunological markers, and more recently, molecular markers. The prognosis of ALL has much improved in the last 30 yr, especially in the age group between 2 and 10 yr, where most patients can be cured by chemotherapy.
Vishwas S. Sakhalkar, Reinhold Munker
openaire +2 more sources
Pharmacogenetics of acute lymphoblastic leukemia
Current Opinion in Hematology, 2004The outcome in children with acute lymphoblastic leukemia has improved significantly over the past four decades. Current therapy results in event-free survival exceeding 80% for most patients. The development of risk-adapted therapy based on characteristics of the child (age), leukemia (leukocyte count, acquired genetic characteristics) and early ...
Stella M. Davies, Parinda A. Mehta
openaire +3 more sources
Acute lymphoblastic leukemia in adults
Current Treatment Options in Oncology, 2000The therapy of acute lymphoblastic leukemia (ALL) in adults has built on the remarkable success achieved in the treatment of this disease in children. However, older age and other adverse risk factors seen more commonly in adults than in children have lessened the success of the treatment of ALL in comparison with what has been achieved in children ...
openaire +3 more sources
Acute Lymphoblastic Leukemia of Childhood
Hematology/Oncology Clinics of North America, 1987Over the last 20 years, the rate of long-term disease-free survival of childhood acute lymphoblastic leukemia increased from less than 1 to 60 per cent. Strategies for disease control include (1) intensive multiagent induction to rapidly decrease the tumor burden and minimize the chance of emergence of a resistant population of cells, (2) restoration ...
openaire +3 more sources
Immunophenotyping of Acute Lymphoblastic Leukemia
2019Immunophenotyping by flow cytometry is an important component in the diagnostic evaluation of patients with acute lymphoblastic leukemia. This technique further permits the detection of minimal residual disease after therapy, a robust prognostic factor that may guide individualized treatment.
Joseph A. DiGiuseppe +1 more
openaire +3 more sources
Acute Lymphoblastic Leukemia in Childhood
Pediatric Clinics of North America, 1985This article reviews those factors that have been responsible for progress in the past, describes current biologic and therapeutic approaches to ALL, and discusses those unresolved treatment issues that pose the major challenge for the future.
openaire +3 more sources